Drug intelligence / Profile preview

atezolizumab + vinorelbine

Development stage: Unknown
Lead developer: Roche
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

This combination involves **atezolizumab**, a monoclonal antibody that acts as an immune checkpoint inhibitor by targeting PD-L1, and **vinorelbine**, a semi-synthetic vinca alkaloid that inhibits microtubule assembly, leading to cell cycle arrest and apoptosis. The combination is explored in various cancer treatments, including non-small cell lung cancer (NSCLC) and breast cancer.

Targets

CD274 (Programmed cell death protein 1 ligand 1)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on atezolizumab + vinorelbine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atezolizumab + vinorelbine.

Explore the full profile